Metvid 50/1000mg Tablet

Metvid 50/1000mg Tablet is a combination medication containing two active ingredients: Vildagliptin & Metformin. It is formulated as an oral tablet for the treatment of type 2 diabetes mellitus.

Active Ingredients:

1. Vildagliptin: Vildagliptin belongs to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors. It works by inhibiting the enzyme DPP-4, which increases the levels of incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These hormones stimulate insulin secretion and inhibit glucagon release, thereby reducing blood glucose levels.
2. Metformin: Metformin is a biguanide antidiabetic agent that primarily reduces hepatic glucose production and increases insulin sensitivity in peripheral tissues. It also improves glucose uptake and utilization by skeletal muscle.

Uses:

Metvid 50/1000mg Tablet is indicated for the treatment of type 2 diabetes mellitus in adults:

• It helps to improve glycemic control by lowering fasting and postprandial blood glucose levels.
• The combination of Vildagliptin and Metformin provides complementary mechanisms of action, resulting in improved efficacy compared to either drug alone.

Mechanism of Action:

Vildagliptin and Metformin work through different mechanisms to achieve blood glucose control:

• Vildagliptin inhibits DPP-4 enzyme activity, leading to increased levels of GLP-1 and GIP, which stimulate insulin secretion and inhibit glucagon release.
• Metformin reduces hepatic glucose production, enhances insulin sensitivity, and improves peripheral glucose uptake.

Administration:

Take Metvid 50/1000mg Tablet orally, with meals, as directed by a healthcare professional. The dosage may vary depending on the patient’s glycemic control and renal function. It is essential to adhere to the prescribed regimen and follow up with regular monitoring of blood glucose levels.

Side Effects:

Common side effects of Metvid 50/1000mg Tablet may include:

• Nausea or vomiting
• Diarrhea
• Abdominal discomfort
• Headache
• Hypoglycemia (low blood sugar) when used with other antidiabetic medications

Precautions:

• Patients with renal impairment should use Metvid with caution, as both Vildagliptin and Metformin are excreted primarily by the kidneys. Dose adjustments may be necessary based on renal function.
• Hypoglycemia may occur when Metvid is used in combination with other antidiabetic medications, particularly insulin or sulfonylureas. Close monitoring of blood glucose levels is recommended.

Contraindications:

Metvid 50/1000mg Tablet is contraindicated in patients with:

• Hypersensitivity to Vildagliptin, Metformin, or any components of the tablet.
• Severe renal impairment (eGFR less than 30 mL/min/1.73 m²) or end-stage renal disease.
• Acute or chronic metabolic acidosis, including diabetic ketoacidosis.